Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 9/20 | 0.53 |
| ▸ | MME | P08473 | 8/20 | 0.53 |
| ▸ | CPA1 | P15085 | 8/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 8/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813707 | 1.00 | ACACB (0.57) | ACACBACEMMECPA1ACE2 | |
| SCHEMBL6818126 | 0.89 | GAA (0.57) | ACACB | |
| SCHEMBL6818123 | 0.89 | GAA (0.57) | ACACB | |
| SCHEMBL6817238 | 0.88 | ACE (0.54) | ACEMMECPA1ACE2ITGB3 | |
| SCHEMBL6817237 | 0.88 | ACE (0.54) | ACEMMECPA1ACE2ITGB3 | |
| SCHEMBL6817369 | 0.83 | ACACB (0.57) | ACACBPPARGPPARA | |
| SCHEMBL13031464 | 0.79 | FPR2 (0.60) | ACEMMECPA1ACE2 | |
| SCHEMBL6817962 | 0.79 | IL1RN (0.52) | ACACBACEMMECPA1ACE2 | |
| SCHEMBL6817956 | 0.79 | IL1RN (0.52) | ACACBACEMMECPA1ACE2 | |
| SCHEMBL12990186 | 0.78 | MME (0.54) | ACACBACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
| EP-1237857-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040170-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | ACACB 90/4885ACE 689/4885MME 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.